CLN-617

However, the only approved human IL-2 therapy, Proleukin, is rarely used in the clinic due to systemic toxicities, and no IL-12 product has been approved to date due to severe dose-limiting toxicities. We found that IT administration of a murine surrogate of CLN-617, mCLN-617, eradicated established treated and untreated tumors in syngeneic models, significantly improved response to anti-PD1 checkpoint therapy, and generated a robust abscopal response dependent on cellular immunity and antigen cross-presentation. CLN-617 is being evaluated in a clinical trial in patients with advanced solid tumors (NCT06035744).

P1, N=86, Recruiting, Cullinan Oncology, LLC | Not yet recruiting --> Recruiting

Secondary endpoints involve the assessment of pharmacokinetics, pharmacodynamics, and immunogenicity across the 3 parts of the trial. Patients’ enrollment is currently ongoing, and updates will be provided at the time of the presentation.